Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Myasthenia gravis is an autoimmune disorder causing muscle weakness that worsens with activity and improves with rest. It ...

AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

The landscape of gMG treatment is rapidly evolving, said John Morren, MD, of the Cleveland Clinic. The traditional approach to managing gMG involves broad immunosuppressive therapies, but emerging ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...